Pegylated interferon and ribavirin therapy for hepatitis C causing cataract.
Ku
Jae Yee
JY
Sharma
Anil
A
D000998:Antiviral Agents / Q000009:adverse effects*; D002386:Cataract / Q000139:chemically induced* / Q000175:diagnosis; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007908:Lens, Crystalline / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D014792:Visual Acuity
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a